Product Development Agreement Sample Clauses

Product Development Agreement eBay and PayPal shall execute and deliver a product development agreement (the “Product Development Agreement”), effective as of the Effective Time, that provides for eBay and PayPal to mutually discuss in good faith and agree on a product development plan for improving the PayPal experience on eBay Covered Properties and to prioritize those improvements to be incorporated into the experience on the eBay Covered Properties (the “Product Development Plan”). The Product Development Plan shall set forth, at a minimum, a description of each development project to which eBay and PayPal mutually agree (each such project, a “Development Project”), the primary owner (eBay or PayPal), the Party with primary responsibility for the achievement of each action item or deliverable for each such Development Project, the expected timeline and key milestones for each such Development Project, the anticipated budget for each such Development Project, and the resource commitments by eBay and PayPal towards completing each such Development Project. The Product Development Agreement shall also provide, among other things, for each of eBay and PayPal to agree to commit resources and development staff, as mutually agreed by eBay and PayPal, to the Development Projects included in the Product Development Plan. ARTICLE VI REFERRAL SERVICES FEES; USAGE OF SERVICES; MARKETING
Sample 1Sample 2
AutoNDA by SimpleDocs
Product Development Agreement. Sellers shall cause to be delivered to Purchaser the Product Development Agreement, duly executed by R. Popeil and Alan Backus.
Sample 1Sample 2
Product Development Agreement. 7.1. As a condition to this contest, pursuant to being selected as winner of this contest, each such winner shall enter into a Product Development Agreement with the Company, in order to be rewarded with the winning cash prize as mentioned in the prize declaration communication.
Sample 1
Product Development Agreement. Revision of the Product Development Agreement Pursuant to the Product Development Agreement entered into between SharkNinja Europe and JS Global Trading dated July 29, 2023 (New York time)/July 30, 2023 (Hong Kong time), the Group will engage the SharkNinja Group to develop market tailored products for Asia Pacific Region and Greater China markets, and provide certain related business support services, for which the SharkNinja Group will charge service fees to the Group for three years from July 31, 2023 upon the completion of the Spin-off, subject to renewal upon mutual consent of both parties. On March 28, 2024, SharkNinja Europe and JS Global Trading entered into an Amendment to Product Development Agreement to revise the service fees and its payment terms of the service fees and tooling costs arrangement under the Product Development Agreement (the “Amendments of PDA”). Save for the said revisions, all other terms and conditions under the Product Development Agreement remain unchanged. Pricing policies The service fee to be charged by the SharkNinja Group to the Group under the Product Development Agreement shall be determined between the Group and the SharkNinja Group on normal commercial terms after arm’s length negotiations on a cost-plus basis, taking into consideration the number of products to be developed by the SharkNinja Group, the cost to be borne by the development personnel of the SharkNinja Group with a reasonable profit margin and the prevailing market rate for providing similar services by SharkNinja Group. Historical Amount For the year ended December 31, 2023 (US$ million) Transaction amount 0.4 From January 1, 2024 to March 31, 2024, the transaction amount under the Product Development Agreement was US$0.5 million.
Sample 1
Product Development Agreement. As of the date hereof, the Parties shall amend that certain Product Development Agreement entered into as of May 9, 2000 (as amended in accordance herewith, the "Product Development Agreement") for the design and development of new NAND Flash Memory Products and NAND Flash Memory-related controllers in the form of Exhibit H attached hereto (the "Amendment to Product Development Agreement").
Sample 1
Product Development Agreement. As of the date hereof, the Parents shall enter into a joint development agreement (the "PRODUCT DEVELOPMENT AGREEMENT") for the design and development of new NAND Flash Memory Products and NAND Flash Memory-related controllers in the form of EXHIBIT E attached hereto.
Sample 1
Product Development Agreement. 31 52. SALES/MARKETING PLAN................................................. 31
Sample 1
AutoNDA by SimpleDocs
Product Development Agreement. (IF APPLICABLE) If a Product Development Agreement (PDA) was executed by the Parties and contains some or all of the Products covered by this Agreement, that Agreement is hereby incorporated by reference insofar as it is not inconsistent with the provisions of this Agreement. For reference, the Product Development Agreement Numbers are shown in Appendix L. 52. SALES/MARKETING PLAN (APPENDIX M) The Sales/Marketing Plan jointly developed and attached hereto as Appendix M represents the parties current plan to sell and distribute Products within their distribution channel. The Sales/Marketing Plan shall be reviewed no less than annually. * INDICATES THAT MATERIAL HAS BEEN OMITTED AND CONFIDENTIAL TREATMENT HAS BEEN REQUESTED THEREFORE. ALL SUCH OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SEC PURSUANT TO RULE 24B-2.
Sample 1
Product Development Agreement. The Parties acknowledge and agree that:
Sample 1

Related to Product Development Agreement

  • Product Development Attach all requested documentation and attach additional pages as necessary. For all requirements include efforts of all Sublicensees. If not applicable, please so indicate by N/A.

  • Development Agreement As soon as reasonably practicable following the ISO’s selection of a transmission Generator Deactivation Solution, the ISO shall tender to the Developer that proposed the selected transmission Generator Deactivation Solution a draft Development Agreement, with draft appendices completed by the ISO to the extent practicable, for review and completion by the Developer. The draft Development Agreement shall be in the form of the ISO’s Commission-approved Development Agreement for its reliability planning process, which is in Appendix C in Section 31.7 of Attachment Y of the ISO OATT, as amended by the ISO to reflect the Generator Deactivation Process. The ISO and the Developer shall finalize the Development Agreement and appendices as soon as reasonably practicable after the ISO’s tendering of the draft Development Agreement. For purposes of finalizing the Development Agreement, the ISO and Developer shall develop the description and dates for the milestones necessary to develop and construct the selected project by the required in-service date identified in the Generator Deactivation Assessment, including the milestones for obtaining all necessary authorizations. Any milestone that requires action by a Connecting Transmission Owner or Affected System Operator identified pursuant to Attachment P of the ISO OATT to complete must be included as an Advisory Milestone, as that term is defined in the Development Agreement. If the ISO or the Developer determines that negotiations are at an impasse, the ISO may file the Development Agreement in unexecuted form with the Commission on its own, or following the Developer’s request in writing that the agreement be filed unexecuted. If the Development Agreement is executed by both parties, the ISO shall file the agreement with the Commission for its acceptance within ten (10) Business Days after the execution of the Development Agreement by both parties. If the Developer requests that the Development Agreement be filed unexecuted, the ISO shall file the agreement at the Commission within ten (10) Business Days of receipt of the request from the Developer. The ISO will draft, to the extent practicable, the portions of the Development Agreement and appendices that are in dispute and will provide an explanation to the Commission of any matters as to which the parties disagree. The Developer will provide in a separate filing any comments that it has on the unexecuted agreement, including any alternative positions it may have with respect to the disputed provisions. Upon the ISO’s and the Developer’s execution of the Development Agreement or the ISO’s filing of an unexecuted Development Agreement with the Commission, the ISO and the Developer shall perform their respective obligations in accordance with the terms of the Development Agreement that are not in dispute, subject to modification by the Commission. The Connecting Transmission Owner(s) and Affected System Operator(s) that are identified in Attachment P of the ISO OATT in connection with the selected transmission Generator Deactivation Solution shall act in good faith in timely performing their obligations that are required for the Developer to satisfy its obligations under the Development Agreement.

  • Collaboration Agreement The Collaboration Agreement shall not have been terminated in accordance with its terms and shall be in full force and effect.

  • Joint Development If joint development is involved, the Recipient agrees to follow the latest edition of FTA Circular 7050.1, “Federal Transit Administration Guidance on Joint Development.”

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Research Support opioid abatement research that may include, but is not limited to, the following:

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Initial Development Plan Not later than the Effective Date, Licensee shall have provided Merck with an initial Development plan for the Licensed Product in the Field in the Territory, which shall be incorporated as part of this Agreement as Attachment 3.02(a) (as may be amended in accordance with this Agreement, the “Development Plan”). **CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  • Marketing Agreement The Company shall have entered into, ------------------- executed and delivered the Marketing Agreement.

  • Clinical Development Licensee will have sole responsibility for and sole decision making over the clinical development of any Product arising from the Research Program in the Field. Notwithstanding the foregoing, if Licensee wishes to conduct clinical development of a Development Candidate at Penn and Penn has the clinical expertise, interest and ability to run such a trial as assessed at Penn’s sole discretion, such a study will be conducted under a separate Clinical Trial Agreement to be negotiated by the Parties prior to initiation of such study. Such separate clinical trial agreement will include a detailed clinical development plan, including costs and time lines for conducting the Clinical Trial.

Time is Money Join Law Insider Premium to draft better contracts faster.